                         SEQUENCE LISTING

<110>  Dignify Therapeutics
 
<120>  COMPOSITIONS FOR INDUCING URINARY VOIDING AND DEFECATION

<130>  336/9 PCT

<150>  US 62/561,387
<151>  2017-09-21

<160>  11    

<170>  PatentIn version 3.5

<210>  1
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Leu at position 6 is methylated at the nitrogen

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Met at position 7 has a NH2 group at the carboxyl terminus

<400>  1

Asp Lys Phe Val Gly Leu Met 
1               5           


<210>  2
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Leu at position 6 is methylated at the nitrogen

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X at position 7 is norleucine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X at position 7 is norleucine that has a NH2 group at the carboxy
       terminus

<400>  2

Asp Arg Phe Val Gly Leu Xaa 
1               5           


<210>  3
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Leu at position 6 is methylated at the nitrogen

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Met at position 7 has a NH2 group at the carboxyl terminus

<400>  3

Asp Arg Phe Val Gly Leu Met 
1               5           


<210>  4
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Met at position 7 has a NH2 group at the carboxyl terminus

<400>  4

Asp Lys Phe Val Gly Leu Met 
1               5           


<210>  5
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Ala at position 5 is beta Ala

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Met at position 7 has a NH2 group at the carboxyl terminus

<400>  5

Asp Lys Phe Val Ala Leu Met 
1               5           


<210>  6
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X at position 7 is a norleucine that has a NH2 group at the 
       carboxyl terminus

<400>  6

Asp Lys Phe Val Gly Leu Xaa 
1               5           


<210>  7
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Ala at position 5 is beta Ala

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X at position 7 is norleucine that has a NH2 group at the 
       carboxyl terminus

<400>  7

Asp Lys Phe Val Ala Leu Xaa 
1               5           


<210>  8
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Met at position 7 has a NH2 group at the carboxyl terminus

<400>  8

Asp Arg Phe Val Gly Leu Met 
1               5           


<210>  9
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Ala at position 5 is beta Ala

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Met at position 7 has a NH2 group at the carboxyl terminus

<400>  9

Asp Arg Phe Val Ala Leu Met 
1               5           


<210>  10
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X at position 7 is a norleucine that has a NH2 group at the 
       carboxyl terminus

<400>  10

Asp Arg Phe Val Gly Leu Xaa 
1               5           


<210>  11
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Ala at position 5 is beta Ala

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X at position 7 is a norleucine that has a NH2 group at the 
       carboxyl terminus

<400>  11

Asp Arg Phe Val Ala Leu Xaa 
1               5           


